发布求助
文献互助 智能选刊 最新文献

Brain and Nerve最新文献

筛选
英文 中文
[Blood Biomarkers for Alzheimer's Disease: Current Status and Prospects]. [阿尔茨海默病的血液生物标志物：现状与前景]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202730
Takeshi Ikeuchi
{"title":"[Blood Biomarkers for Alzheimer's Disease: Current Status and Prospects].","authors":"Takeshi Ikeuchi","doi":"10.11477/mf.1416202730","DOIUrl":"10.11477/mf.1416202730","url":null,"abstract":"<p><p>Blood biomarkers are minimally invasive, are available at a relatively low cost, and are easily accessible; therefore, they are expected to play a pivotal role in the diagnosis of dementia. Measurement of the amyloid-β ratio and phosphorylated tau in plasma has shown high potential for accurate detection of brain pathology in patients with Alzheimer's disease. Studies have investigated blood biomarkers that reflect neurodegeneration and neuroinflammation in patients with dementia. Challenges associated with blood biomarker use include the lack of robustness of the test and the role of confounders that potentially prevent their immediate clinical application. Further real-world studies are warranted to validate the usefulness of blood biomarkers in dementia management. Appropriate recommendations for the use of blood biomarkers for dementia have been published for physicians and investigators, both in Japan and overseas. Considering the versatility of blood biomarkers, they should be cautiously introduced for clinical use.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1045-1052"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Novel Therapeutic Strategies for Alzheimer's Disease]. [阿尔茨海默病的新型治疗策略]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202732
Taisuke Tomita
{"title":"[Novel Therapeutic Strategies for Alzheimer's Disease].","authors":"Taisuke Tomita","doi":"10.11477/mf.1416202732","DOIUrl":"10.11477/mf.1416202732","url":null,"abstract":"<p><p>The molecular pathogenesis of Alzheimer's disease (AD) has been elucidated through the biochemical analysis of senile plaques, neurofibrillary tangles, and pathological features of the brains of patients with AD. Genetic analysis, initiated with familial AD investigation, has revealed that Aβ aggregation and accumulation are crucial processes in AD pathogenesis. The success of lecanemab against aggregated Aβ is the result of these efforts. Meanwhile, research on tau as a causative molecule in AD and various other tauopathies is advancing gradually. Furthermore, genetic analysis has revealed that the inflammatory response of glial cells modifies AD pathophysiology; a novel therapeutic strategy for inflammation control is thus currently under consideration. This article summarizes the latest discoveries related to these new therapeutic strategies for AD.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1053-1058"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease]. [阿尔茨海默病中疾病调节药物导致的淀粉样蛋白相关成像异常的发病机制和治疗方法]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202726
Hidekazu Tomimoto
{"title":"[Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease].","authors":"Hidekazu Tomimoto","doi":"10.11477/mf.1416202726","DOIUrl":"10.11477/mf.1416202726","url":null,"abstract":"<p><p>Amyloid-related imaging abnormalities (ARIA) represent the most frequent adverse effect of lecanemab, a monoclonal antibody drug that targets amyloid beta. ARIA is observed in approximately 20% of patients who receive lecanemab. Most patients are asymptomatic; however, some develop serious neurological symptoms, and optimal management remains clinically challenging in such cases. In this review, I summarize the pathomechanism underlying ARIA and associated disorders, in addition to countermeasures for ARIA.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1011-1017"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation]. [阿尔茨海默病中的改变病情药物：适应症和疗效评估]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202725
Atsushi Iwata
{"title":"[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation].","authors":"Atsushi Iwata","doi":"10.11477/mf.1416202725","DOIUrl":"https://doi.org/10.11477/mf.1416202725","url":null,"abstract":"<p><p>The launch of lecanemab (an anti-Aβ antibody) has introduced a new treatment for Alzheimer's disease. In contrast to conventional therapeutic approaches to dementia, this drug requires new concepts in diagnosis, evaluation, and adverse effects. Specifically, evaluation of the efficacy of lecanemab is extremely important because this drug does not prevent but only slows the rate of disease progression. In this report, I have discussed future issues, including my personal viewpoint and also described the guidelines for promotion of the optimal use of lecanemab issued by the Ministry of Health, Labour, and Welfare.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1005-1009"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Tau Positron Emission Tomography: Applications in Diagnosis and Prognosis of Various Diseases]. [Tau 正电子发射断层扫描：在各种疾病诊断和预后中的应用]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202729
Keisuke Takahata, Manabu Kubota, Shin Kurose, Makoto Higuchi
{"title":"[Tau Positron Emission Tomography: Applications in Diagnosis and Prognosis of Various Diseases].","authors":"Keisuke Takahata, Manabu Kubota, Shin Kurose, Makoto Higuchi","doi":"10.11477/mf.1416202729","DOIUrl":"https://doi.org/10.11477/mf.1416202729","url":null,"abstract":"<p><p>Tau positron emission tomography (PET) is a neuroimaging technique that visualizes tau deposition using PET tracers that selectively bind to tau aggregates. Studies have reported the diagnostic and prognostic value of tau PET in Alzheimer's disease and other tauopathies. However, the binding profiles of tau PET drugs vary widely across tauopathies; therefore, an accurate understanding of the disease-specific characteristics is essential for interpretation of tau PET findings. In this review, we discuss the properties of tau-PET agents and their applications in various diseases.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1035-1044"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease]. [抗淀粉样蛋白抗体药物作为阿尔茨海默病的疾病调节疗法]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202723
Kenichiro Sato, Takeshi Iwatsubo
{"title":"[Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease].","authors":"Kenichiro Sato, Takeshi Iwatsubo","doi":"10.11477/mf.1416202723","DOIUrl":"10.11477/mf.1416202723","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a common dementia disorder in the elderly individuals, accounting for approximately 60-70% of all dementia cases. Recently, significant progress has been made in developing and approving anti-amyloid antibody drugs as one of the disease-modifying therapies (DMT) that aim to slow the progression of AD by targeting amyloid-beta accumulation in the brain. Notable drugs such as aducanumab, lecanemab, and donanemab have shown potential in clinical trials, leading to the approval of aducanumab and lecanemab, and approval is also expected for donanemab. Other anti-amyloid drugs such as remternetug and trontinemab are also under development. However, challenges remain, including adverse effects like amyloid-related imaging abnormalities (ARIA) and the need for addressing healthcare preparedness to support their use. This paper outlines the current status of DMT for AD, including the clinical trial results and current applications of these drugs. It also discusses the existing challenges to improve the safety and accessibility of DMTs.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"991-995"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Disease-modifying Drugs for non-Alzheimer Dementias]. [治疗非阿尔茨海默氏痴呆症的改变病情药物]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202733
Takehiro Miyazaki, Shinji Higashi, Tetsuaki Arai
{"title":"[Disease-modifying Drugs for non-Alzheimer Dementias].","authors":"Takehiro Miyazaki, Shinji Higashi, Tetsuaki Arai","doi":"10.11477/mf.1416202733","DOIUrl":"10.11477/mf.1416202733","url":null,"abstract":"<p><p>Neurodegenerative diseases represent the most common cause of dementia. Protein aggregation is upstream in the pathological mechanisms and is a therapeutic target in the development of disease-modifying drugs in this patient population. Notably, α-synuclein or DNA-binding protein of 43kDa (TDP-43) is commonly involved in the pathomechanisms that contribute to non-Alzheimer neurodegenerative diseases. Several immunotherapy clinical trials on α-synuclein have progressed to phase 2, and small-molecule therapeutics are ongoing. With regard to TDP-43, immunotherapies that target protein aggregates are currently being developed, and research is underway to investigate several drugs that target the associated causative gene. Further research is warranted for deeper insight into both disease-modifying drugs; biomarker tests need to be developed to determine their efficacy. However, both proteins aggregate and accumulate in the brain in many neurodegenerative diseases and dementia; therefore, they are therapeutically significant, and future progress is expected in research and development.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1059-1064"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Significance and Response to APOE Genetic Testing in the Anti-amyloid-β Therapy Era]. [抗淀粉样蛋白-β疗法时代 APOE 基因检测的意义和应对措施］
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202728
Takayoshi Shimohata
{"title":"[Significance and Response to APOE Genetic Testing in the Anti-amyloid-β Therapy Era].","authors":"Takayoshi Shimohata","doi":"10.11477/mf.1416202728","DOIUrl":"10.11477/mf.1416202728","url":null,"abstract":"<p><p>Conventionally, APOE genetic testing has not been recommended as a component of the standard diagnostic and management practices for Alzheimer's disease. However, recent research highlights the importance of this test, particularly for assessment of the safety profile of anti-amyloid-β therapies. Therefore, the current United States guidelines for the administration of lecanemab explicitly advise APOE genetic testing. However, integration of this testing into clinical practice is associated with many clinical, ethical, legal, and economic challenges. It is important to initiate comprehensive discussions to address these multifaceted issues in Japan.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1029-1034"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical Implementation of Amyloid PET: Latest Findings and Practical Approaches in the Diagnosis and Treatment of Alzheimer's Disease]. [淀粉样蛋白 PET 的临床应用：阿尔茨海默病诊断和治疗的最新发现和实用方法]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202727
Atsushi Michael Kimura, Hitoshi Shimada
{"title":"[Clinical Implementation of Amyloid PET: Latest Findings and Practical Approaches in the Diagnosis and Treatment of Alzheimer's Disease].","authors":"Atsushi Michael Kimura, Hitoshi Shimada","doi":"10.11477/mf.1416202727","DOIUrl":"10.11477/mf.1416202727","url":null,"abstract":"<p><p>Amyloid PET plays a crucial role in the early diagnosis of Alzheimer's disease and the determination of the feasibility of disease-modifying therapies. It offers several advantages, including high sensitivity and specificity, minimal invasiveness, and the ability to provide spatial evaluation, all of which contribute to the optimization of dementia care. However, proper use and interpretation of the results require a thorough understanding of their limitations. Although careful consideration is necessary when using scans on asymptomatic individuals, clinical applications could broaden if preemptive treatments and high-precision individual risk assessments for the preclinical stage are developed.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1019-1027"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical Utility of Radiographic Signs in Neuroradiology]. [神经放射学中放射征象的临床实用性]。
Brain and Nerve Pub Date : 2024-09-01 DOI: 10.11477/mf.1416202736
Suketaka Momoshima
{"title":"[Clinical Utility of Radiographic Signs in Neuroradiology].","authors":"Suketaka Momoshima","doi":"10.11477/mf.1416202736","DOIUrl":"10.11477/mf.1416202736","url":null,"abstract":"<p><p>Several characteristic radiographic signs associated with various diseases are useful in neuroradiological practice; however, their clinical usefulness varies widely. This article presents some common signs and the associated pathological features, particularly those observed on computed tomography and magnetic resonance imaging or pathognomonic signs that are useful for accurate diagnosis, even in patients with rare diseases.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 9","pages":"1067-1077"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信